Sellas Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
Sellas宣佈Sls009獲得美國FDA罕見兒科疾病治療資格,可用於治療小兒急性淋巴細胞白血病
Sellas Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
Sellas宣佈Sls009獲得美國FDA罕見兒科疾病治療資格,可用於治療小兒急性淋巴細胞白血病
譯文內容由第三人軟體翻譯。